Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 17/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | GMNN | O75496 | 1/20 | 0.72 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27108395 | 1.00 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL23798874 | 1.00 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL23476743 | 1.00 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL23798627 | 1.00 | STING1 (0.89) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL21132927 | 0.97 | STING1 (0.85) | STING1 | |
| SCHEMBL22352059 | 0.96 | STING1 (0.82) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL22434620 | 0.96 | STING1 (0.82) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL22434622 | 0.96 | STING1 (0.82) | STING1LMNAGMNNRAPGEF3BLM | |
| SCHEMBL21202687 | 0.95 | STING1 (0.90) | STING1 | |
| SCHEMBL22292036 | 0.95 | STING1 (0.90) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| WO-2021178818-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | STING1 2/4885LMNA 1780/4885GMNN 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.